HC Wainwright Issues Negative Estimate for BHST Earnings

Key Points

• HC Wainwright cut BioHarvest's Q1 2026 EPS estimate to ($0.11) from ($0.04) and now projects FY2026 EPS of ($0.25), versus the consensus full-year loss of ($0.35).
• Analyst views are mixed—two Buy ratings and one Sell leave a consensus "Hold" with an average price target of $12.50.
• Shares trade around $4.38 with a market cap of about $86 million (12‑month range $4.10–$12.80), and several institutions including Alyeska, Thompson Siegel, Evercore and Osaic recently initiated or boosted stakes.

BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Equities researchers at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for BioHarvest Sciences in a report released on Thursday, April 23rd. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings of ($0.11) per share for the quarter, down from their prior forecast of ($0.04). The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for BioHarvest Sciences' Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.25) EPS.

A number of other equities research analysts have also recently issued reports on BHST. Roth Mkm began coverage on BioHarvest Sciences in a report on Thursday, February 19th. They set a "buy" rating and a $10.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of BioHarvest Sciences in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $12.50.

BioHarvest Sciences Stock Performance

Shares of NASDAQ:BHST opened at $4.38 on Monday. BioHarvest Sciences has a 12-month low of $4.10 and a 12-month high of $12.80. The stock has a market cap of $85.94 million, a PE ratio of -7.18 and a beta of 1.16. The business has a 50 day moving average of $4.38 and a 200-day moving average of $5.93. The company has a quick ratio of 3.38, a current ratio of 3.97 and a debt-to-equity ratio of 0.10.

Institutional Investors Weigh In On BioHarvest Sciences

Several institutional investors have recently made changes to their positions in BHST. Alyeska Investment Group L.P. bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $3,929,000. Thompson Siegel & Walmsley LLC bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $1,945,000. Evercore Wealth Management LLC bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $724,000. King Luther Capital Management Corp bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $208,000. Finally, Osaic Holdings Inc. boosted its stake in shares of BioHarvest Sciences by 5,510.4% in the fourth quarter. Osaic Holdings Inc. now owns 35,233 shares of the company's stock valued at $183,000 after buying an additional 34,605 shares during the period.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company's product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.